得益于FDA审批进展以及持续的并购趋势，ABVX是一个极具吸引力的收购标的。
逐段跳播
Allergan。这只股票自今年年初以来也一直表现不佳。这是一家小型生物技术公司，市值仅为5亿美元。他们正在开发用于治疗癌症和自身免疫性疾病的转基因T细胞疗法。
Allergan. This stock has also been underperforming since the beginning of the year. It is a small biotechnology company, with a market value of only half a billion dollars. They are developing genetically modified T-cell therapies to treat cancer and autoimmune diseases.
我认为它现在已经准备好被大型制药公司收购，因为其药物正走在获得FDA批准的道路上。如果并购的步伐像今年上半年那样持续下去，像Allergan这样的公司将会吸引大型制药公司的关注。
I believe it is ready for acquisition by larger pharmaceutical companies now, given that its drugs are on the path to FDA approval. If the pace of mergers and acquisitions continues as it did in the first half of the year, companies like Allergan will attract the attention of major pharmaceutical companies.
这个频道对 $ABVX 的历次判断
Schwab Network 在这只股票上只有这一条判断。